Analysts Offer Insights on Healthcare Companies: Global Blood Therapeutics (NASDAQ: GBT), Adverum Biotechnologies (NASDAQ: ADVM) and Aquinox Pharmaceuticals (NASDAQ: AQXP)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Global Blood Therapeutics (NASDAQ: GBT), Adverum Biotechnologies (NASDAQ: ADVM) and Aquinox Pharmaceuticals (NASDAQ: AQXP) with bullish sentiments.

Global Blood Therapeutics (NASDAQ: GBT)

In a report issued on November 10, Ritu Baral from Cowen & Co. reiterated a Buy rating on Global Blood Therapeutics (NASDAQ: GBT), with a price target of $83. The company’s shares closed last Friday at $19.55.

Baral noted:

“GBT announced with its 3Q16 update that all clinical programs, including ‘440 in SCD,.”

According to TipRanks.com, Baral is a 4-star analyst with an average return of 6.2% and a 41.7% success rate. Baral covers the Healthcare sector, focusing on stocks such as Protalix Biotherapeutics, Intra-Cellular Therapies, and Anthera Pharmaceuticals.

Currently, the analyst consensus on Global Blood Therapeutics is Strong Buy and the average price target is $83, representing a 324.6% upside.

In a report issued on November 1, Roth Capital also initiated coverage with a Buy rating on the stock with a $47 price target.
Adverum Biotechnologies (NASDAQ: ADVM)

Piper Jaffray analyst Joshua Schimmer reiterated a Buy rating on Adverum Biotechnologies (NASDAQ: ADVM) on November 9 and set a price target of $9. The company’s shares closed last Friday at $3.65.

According to TipRanks.com, Schimmer is ranked 0 out of 5 stars with an average return of -3.7% and a 43.5% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Bellicum Pharmaceuticals, and Voyager Therapeutics Inc.

Adverum Biotechnologies has an analyst consensus of Moderate Buy.

Aquinox Pharmaceuticals (NASDAQ: AQXP)

In a report issued on November 9, Arlinda Lee from Canaccord Genuity reiterated a Buy rating on Aquinox Pharmaceuticals (NASDAQ: AQXP), with a price target of $22. The company’s shares closed last Friday at $13.52.

According to TipRanks.com, Lee is ranked 0 out of 5 stars with an average return of -6.1% and a 44.3% success rate. Lee covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Actinium Pharmaceuticals, and Asterias Biotherapeutics.

Currently, the analyst consensus on Aquinox Pharmaceuticals is Strong Buy and the average price target is $24.50, representing an 81.2% upside.

In a report issued on November 10, Needham also reiterated a Buy rating on the stock with a $25 price target.